Trials / Completed
CompletedNCT01831960
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Intrepid Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in subjects with acne vulgaris ages 12 years or older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cortexolone 17α-propionate |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2013-04-15
- Last updated
- 2020-12-02
- Results posted
- 2020-11-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01831960. Inclusion in this directory is not an endorsement.